To determine if these BRD4-enriched super-enhancers are relevant to ovarian cancer patients, we leveraged the assay for transposase-accessible chromatin at single-cell resolution (scATAC-seq) data generated from HGSOC patients to measure the activity of the super-enhancers within these tumors43. This evidence concerns the gene BRD4 and ovarian carcinoma.